The use of small animal models in basic and preclinical sciences constitutes an integral part of testing new pharmaceutical agents prior to commercial translation to clinical practice. Whole-body small animal imaging is a particularly elegant and cost-effective experimental platform for the timely validation and commercialization of novel agents from the bench to the bedside. Biomedical imaging is now listed along with genomics, proteomics, and metabolomics as an integral part of biological and medical sciences. Miniaturized versions of clinical diagnostic modalities, including but not limited to microcomputed tomography, micromagnetic resonance tomography, microsinglephoton-emission tomography, micropositron-emission tomography, optical imaging, digital angiography, and ultrasound, have all greatly improved our investigative abilities to longitudinally study various experimental models of human disease in mice and rodents. After an exhaustive literature search, the authors present a concise and critical review of in vivo small animal imaging, focusing on currently available modalities as well as emerging imaging technologies on one side and molecularly targeted contrast agents on the other. Aforementioned scientific topics are analyzed in the context of cancer angiogenesis and innovative antiangiogenic strategies under-the-way to the clinic. Proposed hybrid approaches for diagnosis and targeted site-specific therapy are highlighted to offer an intriguing glimpse of the future.
I. INTRODUCTION
The use of small animal models in basic and preclinical sciences constitutes an integral part of testing new pharmaceutical agents prior to commercial translation to clinical practice.
1,2 Nowadays, owing to the development of gene knockout and transgenic techniques, small animals such as mice and other rodents are widely used for experimental modeling in preclinical studies of cardiovascular and neoplastic disorders. 3, 4 Whole-body small animal imaging is a particularly elegant and cost-effective experimental platform for the timely validation and commercialization of novel agents from the bench to the bedside. On average, $800 million and 12 years of research are spent for the successful translation of an experimental compound to human therapy. Only 1 out of 1000 agents tested enter preclinical research and approximately only 1 out of 5000 make it from the bench to the bedside. 5, 6 Preclinical animal imaging is thus of crucial importance in the majority of stages of new drug discovery and development, contributing to high-throughput phenotyping of transgenic animals, profiling of new disease models, pharmacological and pharmacokinetic analysis for target identification, and safety testing and evaluation of drug-effects on host anatomy, function, and metabolism. 7, 8 Imaging is now listed along with genomics, proteomics, and metabolomics as a part of the more general "biomarker concept." Biomarkers are objectively measured, quantitative parameters of normal and abnormal biological processes that serve as indicative end points guiding safety and efficacy of an experimental compound for potential drug development. 7 For example, noninvasive radiological imaging permits evaluation of toxic side-effects on target organs longitudinally in vivo or postmortem without invasive and labor intensive tissue dissection, fixation, and sectioning. micromagnetic resonance tomography ͑micro-MR͒, microcomputed tomography ͑micro-CT͒, optical imaging, and ultrasound, 10 have all greatly improved our investigative abilities to longitudinally study various experimental models of human disease in mice and rodents. 3 Albeit with limited spatial resolution, medium-sized experimental subjects such as rabbits, canines, and mini pigs can be effectively imaged with routine clinical machines ͑Fig. 1͒. The primary and foremost unique advantage of in vivo small animal imaging methodologies is their ability to noninvasively screen, analyze, and monitor the animal subjects before, during, and after the experimental intervention or drug administration producing quantitative surrogate measurements of study outcomes. Noninvasive in vivo monitoring of the expression of cell-specific targets and their drug-induced inhibition, evaluation of tissue pharmacokinetics at the cellular and subcellular level, and early assessment of tissue response are highly desired pharmacological end points that are critical to the design and approval of novel site-targeted drugs and imaging probes. 11 Advances in molecular imaging have already transformed our knowledge of normal and tumor angiogenesis and may permit therapeutic manipulation of the phenomenon on the nanoscale in the future. Angiogenesis refers to the formation of new blood vessels and is implicated in a variety of normal and pathologic inflammatory and malignant conditions. Imaging of molecular targets is crucial not only to the understanding of the pathophysiology of the disease, but also to the development of novel molecular targeted drugs. For example, molecular imaging of integrin expression represents a recent scientific breakthrough in the detection and therapeutic targeting of cancer. [12] [13] [14] In the present article, the authors present a concise and critical review of in vivo small animal imaging focusing on currently available modalities and emerging imaging technologies on one side and molecularly targeted contrast agents on the other. For educational purposes, the aforementioned scientific topics are analyzed in the context of cancer angiogenesis and antiangiogenic strategies for potential use in the clinic. After an exhaustive literature search, proposed hybrid approaches for diagnosis and targeted site-specific therapy are highlighted to offer an intriguing glimpse into the future.
II. ULTRASOUND
Ultrasonography, sonography, or ultrasound ͑all interchangeable synonyms͒ provides anatomical information of soft tissue structures on the basis of differential transmission and reflection of ultrasound ͑typical frequency ranges from 3-5 MHz up to MHz͒ between adjacent tissue layers. The higher the delivered ultrasound frequency, the higher the tissue spatial resolution achieved at the expense, however, of higher attenuation by tissue, resulting to more superficial penetration. 15, 16 Depending on the probe wavelength and the depth of target organ, ultrasound may provide fast, portable, and economical diagnostic imaging with a high frame rate, high resolution, high sensitivity, and sufficient contrast. 17 Notwithstanding its operator-dependent limitations, ultrasound imaging is a highly versatile real-time technique that has proved particularly useful for high throughput anatomical screening of organ disease and pathology on multiple anatomical planes. Typically, high frequency linear or curvilinear broadband transducers operating around 12-15 MHz are employed for solid-organ and soft-tissue imaging of small animals like mice. 18 Ultrasound biomicroscopy is another exciting advancement of ultrasound technology based on ultrahigh frequencies exceeding 20 MHz, up to 100 MHz, able to achieve axial and lateral resolution of 30 and 60 m, respectively. High-resolution ultrasound biomicroscopy has been applied to portray the beating heart of in utero embryonic mice 19, 20 or in cancer research for early detection and quantitative measurement of tumor growth in mice bearing implanted xenografts or even humans with suspected conjunctival melanomas. 21, 22 Ultrasonography employs several real-time techniques, including but not limited to M-mode, which refers to onedimensional imaging of space over time, B-mode, which is two-dimensional imaging over time, three-dimensional static or dynamic imaging, i.e., 4-D, and color-Doppler sonography that provides hemodynamic information about heart and vessel blood flow. Blood cells reflect the incoming acoustic signal with a frequency shift that depends on the angle between their movement direction and the ultrasonic waves. 17 Microvessels, however, usually portray slow blood velocity that is notoriously difficult to be detected with Doppler. Higher ultrasound frequencies ͑up to 40 MHz͒ may increase the sensitivity of Doppler for slow blood flow.
The field of preclinical and clinical ultrasound imaging has been revolutionized by the introduction of dedicated contrast agents. Gas-filled microbubbles ͑MB͒ may detect very slow blood flow of the microcirculation with superb sensitivity and specificity ͑Fig. 2͒. 23 In addition, they may incorporate appropriately designed superficial molecules for sitespecific targeting of imaging with high signal-to-noise ratio ͑SNR͒ ͑see dedicated Sec. XIII͒. Of interest, high-resolution FIG. 1. Whole-body three-dimensional volume-rendered CT images of a New Zealand White ͑NZW͒ rabbit with a routine 16-row detector clinical scanner ͑GE Lightspeed, General Electric Medical Systems, USA͒. Note two different reconstruction techniques highlighting mostly ͓͑a͒ and ͑b͔͒ bones and vessels or ͓͑c͒ and ͑d͔͒ soft tissues. Images ͑a͒ and ͑c͒ are anterior whole-body projections, while ͑b͒ and ͑d͒ are posterior ones.
ultrasound perfusion imaging with a contrast pulse sequence has also been used to study reperfusion and therapeutic angiogenesis by quantitative calculation of blood volume and other perfusion parameters in ischemic muscles of rabbit and mouse hindlimbs.
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III. MICRO-CT
CT and magnetic resonance imaging ͑MRI͒ provide detailed anatomical and functional cross-sectional images of the organs of interest and have received worldwide recognition as two of the most groundbreaking technologies that have virtually transformed modern healthcare services. The Nobel Prize was jointly awarded to Allan M. Cormack and Godfrey N. Hounsfield in 1979 for the invention of CT and to Paul C. Lauterbur and Sir Peter Mansfield in 2003 for the invaluable discovery of MRI. Downscaling of electronics and engineering have led to the development of miniaturized versions of CT ͑micro-CT͒ and MRI ͑micro-MRI͒ that are now commercially available, appropriately tuned, and optimized for small animal imaging in preclinical research. 7, 9, 25 The first micro-CT or x-ray microtomography system was conceived and built by Jim Elliott in 1982. The first published axial micro-CT images were reconstructed slices of a small tropical snail with pixel size around 50 m. 26 Since the appearance of the first seminal papers in the early 1980s, 27,28 the number of publications on small animal micro-CT imaging have increased exponentially. 8 The introduction of cone beam reconstruction algorithms by Lee Feldkamp, developments in x-ray detector sensitivity, and new blood contrast agents allow static or dynamic preclinical imaging with high spatial and temporal resolution for animal phenotyping, disease monitoring, and drug development.
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Modern micro-CT or mini-CT systems provide superb crosssectional images of soft-tissue and skeletal structures with submillimeter spatial resolution, subsecond temporal resolution, and acceptable contrast to differentiate tumor growth, skeletal abnormalities, abnormal lung or heart function, and a multitude of other pathologies. [7] [8] [9] 25, 31, 32 An up-to-date market overview of current commercially available micro-CT scanners for preclinical animal research, including new designs that perform helical acquisitions ͑i.e., Skyscan͒, may be found elsewhere. 8 A typical micro-CT setup involves an x-ay tube and a two-dimensional x-ray detector mounted on exactly opposite positions on a gantry that rotates around the subject of examination. A different construction principle involves the rotation of the examined object inside the path of radiation and is mostly used for micro-CT analysis of vertically fixed ex vivo specimens. 33, 34 Spatial resolution and SNR of micro-CT scanners depends on the operating characteristics of the x-ray tube ͑reflection or transmission target, target material, and tube voltage͒, pixel pitch and matrix size of the detector, distance of the examined object from the radiation source ͑source to object distance͒ and the detector ͑detector to object distance͒, and focal spot size. 9 The bigger the focal spot size is, the higher the penumbra blurring that is caused, e.g., the unsharpness at the edges of the studied object that compromises image quality and tissue contrast. Contrary to conventional clinical CT systems that utilize x-ray tubes with reflection targets and minimum focal spot size of 300 m, most preclinical micro-CT scanners employ transmission targets with a focal spot size ranging from 1 to 10 m. These nanofocus or microfocus x-ray tubes can produce highresolution isotropic voxel imaging on the order of 50 m.
8,9
The emitted x-ray beam can be either fan-shaped, with continuous spiral rotation of the x-ray source around the subject, or cone-beam-shaped ͑e.g., volume CT͒, which scans small objects in just one rotation, is considerably faster, and almost eliminates motion artifacts. Cone-beam micro-CT is particularly useful for cardiac and thoracic imaging in rodents with minimal artifacts from respiratory and heart movements. 8 Detectors used for high-resolution small animal imaging must portray high quantum efficiency, freedom from geometric distortions, and a linear, consistent response over a wide spectrum of x-ray energies. 9 The detectors used for image recording in modern micro-CT systems are charge-coupled device ͑CCD͒ photodetectors optically connected to a scintillator screen made of GdO 2 SO 4 or CSI͑TI͒. 9 Flat panel volumetric micro-CT represents another relatively recent development in the field of cross-sectional preclinical imaging. 35 Active flat matrix panel imagers consist of photodiodes ͑amorphous silicon or a complementary metal-oxide superconductor͒ connected to thin film transistors. 36, 37 Filtered backprojection algorithms are the most commonly used technique for image reconstruction in micro-CT systems. 38 Acquired axial images can be further reformatted to multiplanar reconstructions ͑Fig. 3͒ and volume-rendered views providing a three-dimensional perception of anatomy and morphology.
Experimental micro-CT protocols include but are not limited to in vivo or ex vivo imaging of the skeleton, 39,40 the vascular tree, 41, 42 the heart and lungs with or without gating [43] [44] [45] ͑Fig. 4͒, the brain, 46,47 the kidneys, 8, 48 and the gastrointestinal tract. 49 Micro-CT angiography with bloodpool agents in rodents can achieve isotropic voxel imaging up to 16 m with total scan times less than 1 min. 41 Computed tomography perfusion imaging ͑CTPI͒ with a multidetector clinical scanner can be readily applied for quantitative estimation of blood flow and perfusion of ischemic rabbit hindlimbs when investigating ischemia-driven collateralization and therapeutic arteriogenesis ͑Fig. 5͒. 50 In oncology, detailed micro-CT tomographic imaging can detect and quantify bone metastases, 51, 52 visualize tumor supplying vessels down to 50 m, 37 or even evaluate angiogenic networks with digital subtraction angiography ͑DSA͒ using cone-beam CT platforms. 8, 41 Micro-CT is a particularly robust experimental methodology for detection, morphological analysis, and quantitative scoring of angiogenesis associated with solid tumors or ischemia. 53, 54 Examples of preclinical imaging and evaluation of angiogenesis with micro-CT range from arterial vasa vasorum to xenografts' neovascularization ͑Fig. 6͒. 55, 56 Combined hybrid imaging with integrin-targeted SPECT imaging has been applied to increase the sensitivity of discrimination of active ongoing areas of angiogenesis. 53, 57 Of interest, microcomputed tomography has been used to delineate the three-dimensional microangioarchitecture of tumoral neovascularization in implanted tumors in rabbits. 58 Micro-CT is also applicable to murine models of colorectal cancer. Microcomputed tomography colonoscopy after bowel cleansing and air insufflation in living animals is capable of detecting minute colonic tumors with two-dimensional imaging or three-dimensional fly-through virtual endoscopy and performing volumetric analysis of tumor growth. 49 Exposure of subjects to ionizing radiation represents an increasingly concerning issue for micro-CT applications. Radiation exposure may not be lethal, but adequate to influence organ and cell biology, resulting to biased and misleading experimental data. 59 An increase in dose is required when reducing the isotropic voxel spacing while maintaining the same image quality. For example, image acquisition of mice with a total of 0.25 Gy results in a 135 m isotropic voxel size, whereas up to 5 Gy would be necessary for increased resolution with a 65 m isotropic voxel size.
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IV. MICRO-MRI
MRI imaging is a very powerful and versatile imaging modality. Modern micro-MRI systems provide noninvasive in vivo whole-body small animal imaging with high spatial resolution, around 100 m for rodent studies, and excellent contrast for soft-tissue differentiation. 7 Clinical 1.5-3.0 T MRI scanners can be also used for targeted molecular imaging of angiogenesis and phenotypic characterization of nascent solid tumors in medium-sized animals such as rabbits. 61 MRI is generally based on the manipulation of the magnetic properties of water hydrogen atoms ubiquitously present in living organisms within a high-strength static magnetic field of the order of 0.5-9.4 T. 62 A series of repetitive radiofrequency pulses and gradients are applied to excite the spins of hydrogen atoms, followed by Fourier space sampling to reconstruct multiplanar images of the organ͑s͒ of interest. Medical physicists have developed a variety of sophisticated MRI sequences capable of extracting a wealth of information about anatomy, morphology, function and metabolism. Particular strengths of preclinical MRI include dynamic visualization of tissue perfusion, diffusion and blood flow dynamics that can be exploited for high-sensitivity studies of tumor angiogenesis. Magnetic resonance spectroscopy ͑MRS͒ involves the identification of the spectra of different atomic nuclei, such as hydrogen, carbon, phosphorus, and fluorine, of specific regions of interest, thereby providing functional and biochemical information about a wide range of biological processes. Examples of cell metabolites measured with MRS include choline that is contained in cell membranes, creatine and glucose involved in energy production, and alanine and lactate that are characteristically increased in some tumors. Despite being significantly less sensitive than PET and SPECT, MRS can be applied for localization and measure- ments of endogenous metabolites and mediators in the central nervous system and the heart. 63, 64 The technique is particularly unique in identifying the metabolomic fingerprint of single cells up to isolated perfused organs, which can be further used for the discovery of novel biomarkers of disease. 65, 66 Compared to PET, which boasts the highest sensitivity with detection capabilities of radiolabeled agents in the picomolar scale, SPECT requires 10 1 -10 2 higher amounts of tracer and MRI 10 7 -10 8 more. 7 Therefore, MRS's contribution in preclinical research is primarily confined to pharmacodynamic, but not pharmacokinetic studies. Whereas pharmacokinetics study the absorption, distribution, metabolism, and excretion of drugs, pharmacodynamics focuses on the physiological effects and mechanisms of drug action and interaction with the human body or other organisms. For instance, 19 F, 31 P, 1 H, and 13 C MRS has been applied to detect the biodistribution of appropriately labeled anticancer drugs. 67, 68 High-strength magnetic fields in the order of 9.4 T with advanced shimming have achieved acquisition of high-resolution proton spectra of the mouse brain. 69 A key area of MRS application in small animal imaging includes the identification of the levels of cell-specific metabolites within implanted tumor xenografts. 70, 71 MRS has been also applied in cancer murine models for the evaluation of tumor response after therapy with vascular-disrupting agents, pinpointing total choline levels as a potential biomarker for spectroscopic follow-up of successful antiangiogenic therapy. 72, 73 Functional MRI ͑fMRI͒ refers to imaging and anatomic identification of specific areas of the brain excited while performing a particular task. Literature reports of fMRI application in murine models are scarce because of practical chal- FIG. 5 . CTPI in a model of experimental hindlimb ischemia. Base image ͑A͒ at the level of the thighs 10 days after endovascular embolization and occlusion of the left femoral artery in a NZW rabbit. Note the hypodense appearance of the chronically ischemic muscles in the left hindlimb ͑white arrows͒. Graph ͑B͒ illustrates temporal contrast density in the rabbit abdominal aorta ͑curve 1 with early arterial peak͒ and inferior vena cava ͑curve 2 with late sustained enhancement͒ used for further deconvolution analysis and quantitative calculation of blood perfusion parameters such as ͑C͒ blood flow expressed in mls per min per 100 g of tissue and ͑D͒ blood volume expressed in mls per min.
lenges and technological limitations with regard to available radiofrequency coils. 74, 75 Manganese-enhanced T1-weighted MRI evaluates cerebral blood volume and oxygen levels on the basis of increased uptake of paramagnetic manganese in areas of brain tissue that exhibit increased activity when the awake animal is exposed to a repeated stimulus or performs a particular task. 7, 75 Anesthesia is prohibited and applied stimuli must be constant or repeated to affect biodistribution of manganese. Then, localized increased uptake identifies the exact anatomical location where the respective excited neuronal networks reside. Functional MRI with gadoliniumdiethylenetriaminepenta-acetic acid has been long introduced in clinical practice for evaluation of kidney glomerular filtration and renal split function.
V. DIGITAL ANGIOGRAPHY
Experimental studies of angiogenesis and tumor neovascularization can further benefit from functional and anatomic imaging with digital angiography, first suggested in 1973. 76 DSA imaging involves the injection of an intravascular contrast agent and rapid acquisition of two-dimensional images of a region of interest before and during contrast circulation. Precontrast images are digitally subtracted from postcontrast images to visualize the vasculature with a very high SNR. Already in routine clinical practice, DSA is a relatively easy to use, low-cost technique for vessel imaging with high spatial and temporal resolution, around 90-100 m and 140 ms, respectively. Large focal spot size with exposure times less than 10 ms are generally necessary in preclinical DSA protocols for fast image acquisition. 9 Computer-controlled microinjectors are necessary for small animal applications to optimize reproducibility of injection dose, pressure, and rate of contrast boluses. 77 Small animal DSA has been applied for lung perfusion imaging or coronary artery angiography with gating techniques to avoid motion artifacts, or for visualization of tumor or liver or kidney microvessels down to 46 m resolution. 78 Combined micro-CT and micro-DSA with iodinated blood pool and conventional contrast media, respectively, has been applied in animal models of fibrosarcoma to provide coregistered information that combine the exquisite threedimensional angioarchitecture of micro-CT with the functional hemodynamics of digital subtraction angiography in order to analyze tumor angiogenesis and monitor antiangiogenic therapies. 79 Tomosynthesis reconstruction techniques, e.g., tomographic DSA, has been recently developed to provide three-dimensional images instead of plain twodimensional projections of traditional DSA. 80, 81 Plain digital x-ray radiographs are rapidly acquired after contrast injection over a specific sampling arc around the object of interest, followed by computerized tomographic reconstruction of multiangle projection images that can be further rendered to volumetric images, also called rotational or threedimensional angiography. 4-D data sets can be also obtained to provide perfusion analysis of a volume of tissue, such as the lungs, over time. 9, 32 Computerized postprocessing of raw DSA images is particularly useful for vessel segmentation and high-resolution quantitative vascular mapping of neovascular and collateral angiogenic microcirculation in the context of cancer 82 or ischemia-driven tissue reperfusion down to the 50 m scale ͑Fig. 7͒. 
VI. MICRO-SPECT
SPECT imaging is based on the detection of gamma photons, which are emitted from radiotracers that concentrate in target areas of an animal or a human. The main detector component of a clinical SPECT system is the Anger gamma camera. 84 A lead or tungsten collimator, with usually hexagonal parallel holes, determines the photons that will be accepted. The collimator is the main limiting factor of a SPECT system's resolution and sensitivity and its optimization is still an open issue, especially in dedicated systems. 85 A scintillator converts each accepted photon, with energies that vary between 90 and 300 keV, to thousands of optical photons with energies of a few eV. 86, 87 The scintillator is coupled to a photomultiplier tube ͑PMT͒, usually by using an optical light-guide such as silicon fluid, grease, or Lucite light pipes. Optical photons strike on the PMT's photocathode and photoelectrons are emitted. By applying a high voltage ͑close to Ϫ1000 V͒ to a multidynode stage, those electrons are multiplied and an electron cloud hits the PMT's anode. Usually, four signals are obtained, which need to be amplified, digitized, and used to calculate the position of each incident photon. When the gamma camera is rotated around the object to be imaged, projection data are obtained and by using convolution or iterative algorithms, tomographic SPECT images are reconstructed. 88 Two major advantages of SPECT are the existence of several radiotracers that are based on a variety of radioisotopes with different energies and their relatively long half-life that makes them easily accessible to many research groups. As a consequence, those tracers have been well studied and used not only for tumor probing but also in several biological applications in animal models. 89 The increased need for dedicated animal studies has pushed SPECT technology over the past 15 years. In collimator design, the optimization of resolution and sensitivity has led to systems with submillimeter resolution. 90 Multipinhole systems can improve sensitivity by allowing acquisition of several overlapping images. 90, 91 Significant advances have occurred in scintillators research; although all clinical SPECT cameras are using NaI͑Tl͒, several new materials including CsI͑Tl͒, CsI͑Na͒, and LaBr3:Ce offer improved light output, energy resolution or PMT coupling, and have been applied in dedicated systems. 87 However, the major difference compared to clinical systems is the use of pixilated scintillators, which provide a focused light spot on the PMT entrance window. Although this is not desirable when Anger logic is used, it is highly valuable when the photomultiplier can provide position information; then the pixel size ͑now down to 1 ϫ 1 mm 2 ͒ practically determines system resolution. Position sensitive photomultiplier tubes ͑PSPMTs͒ were introduced by the end of the 1990s and they fulfill this need. The design of their dynode stage and cross wired or pixilated anode maintains position information during electrons multiplications, 92 making possible the construction of small field of view detectors with very high resolution. Several improvements in the field of electronics have also assisted to the improvement of systems sensitivity, as well as dramatic decrease in their overall size and cost. 93 Nowadays, several groups are working on the development or application of small gamma cameras based on pixilated scintillators coupled to PSPMTs. [94] [95] [96] The use of solid state ͑and mainly cadmium zinc telluride͒ systems offers an alternative to the combination of the scintillator-PMT module. Solid state detectors allow direct photon detection and they are characterized by significantly higher energy resolution. 97 This can be crucial in applications where multiple radiotracers are administered in small animals or even humans. 98 However, the development of such systems has several technical challenges, which limits their spread. Recently, the introduction of silicon photomultipliers ͑SiPMs͒ as a prominent alternative to PMTs is being investigated for application in SPECT. SiPMs have a gain similar to PMTs, they are offered in arrays that can be coupled to pixilated scintillators, and they operate at low voltages ͑30-70 V͒. 99 Since their performance is improved and their cost continuously decreases, they are expected to play a significant role in the near future of SPECT technology.
Scintigraphic and SPECT imaging has been used in clinical practice over the past 30 years, being the first clinical molecular imaging method. Myocardial SPECT ͑stress, rest, and gated͒, thyroid imaging, and whole-body bone scintigraphy have become routine applications. Other clinical protocols include brain SPECT, dynamic renal scintigraphy, dementia, and other more specific applications. 100 SPECT has an increasing role in oncology, due to a number of novel radiopharmaceuticals that are designed for specific tumors ͑Fig. 8͒. 101 Radiopharmaceuticals research has been the field of application of the first preclinical scanners. 102 However, the high spatial resolution and sensitivity that they offered opened new paths for preclinical SPECT and pushed molecular imaging to other exciting applications including neurodegenerative diseases, psychiatric disorders, inflammation, gene expression, and protein function. Preclinical oncology remains an area of active research; besides tumor receptors, numerous studies are focused in relative functions such as cell apoptosis, hypoxia, and angiogenesis. 103 In the latter, SPECT has been used to image integrin avb3 expression, VEGF, extracellular matrix, activated endothelial cells, and matrix metalloproteinases. 104 Absorbed radiation dose in SPECT is significantly lower than in CT human studies; however, the introduction of SPECT/CT is again raising dosimetry issues, especially in common diagnostic exams such as cardiac imaging. 105 Although in the early days of preclinical imaging absorbed dose was not studied, its rapid spread, the need for repeated studies in the same animal, and the relatively high concentrations of tracers used ͑compared to human examinations͒ has led to careful dose monitoring and reduction of injected administered activity. The results of a Monte Carlo study indicate that typical values for whole body dose in mice are 0.33, 0.36, and 1.2 cGy for Tl-201, In-111, and Tc-99m, respectively.
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VII. MICRO-PET
PET imaging has several similarities with SPECT, since it includes the injection of a radiotracer and photon detection. However, a number of differences, which affect detector design and potential end-applications, must be highlighted. PET radiopharmaceuticals emit mainly positrons instead of photons. The positrons emitted by PET radioisotopes have differences in their kinetic energy. The higher its kinetic energy is, the longer the distance ͑up to a few millimeters͒ that a positron travels and when it hits an electron they annihilate, producing two antiparallel photons. Their energy is always equal to 511 keV; thus, PET does not have the advantage of using multiple tracers simultaneously. A PET detector must be capable of detecting those photons traveling in opposite direction; thus, its minimum requirement is the existence of two opposite detectors, while a full ring system maximizes the sensitivity of the technique. 107 In conventional systems, those photons are detected by using the combination of a scintillator, a PSPMT, and amplification and digitization electronics, as it has been described in Sec. VI. The most important hardware difference between PET and SPECT is the absence of a collimator ͑Table I͒. The trajectory of the annihilation point is determined by the line that connects the two photons ͑line-of-response͒ that were detected in a short time window ͑usually 4-20 ns͒. This technique is referred to as electronic collimation. The position of the annihilation point is calculated by applying a reconstruction algorithm. The absence of the collimator significantly improves the sensitivity of PET, especially when 3D data are obtained and sensitivity can be up to 100 times greater than SPECT. The factors that limit resolution are mainly positron range, photons noncollinearity, scattering in the medium or in the detector, attenuation, and random events. Those effects become more important in large clinical systems and although several techniques to minimize them are applied, 108 PET resolution ranges from 4 mm in everyday clinical systems down to 1 mm in dedicated preclinical scanners ͑Fig. 9͒.
Evolution in dedicated PET imagers has resulted in several prototypes and preclinical commercial systems. 109 There The combination of more than two scintillators ͑phoswich detectors͒ provides more accurate information regarding photon's depth of interaction in the crystal, since the pulse time characteristics depend on crystal material properties.
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Rapid evolutions in electronics have led to a new generation of compact amplifiers and apparent diffusion coefficients ͑ADCs͒ that have a temporal resolution of the order of a few picoseconds. This makes possible the calculation of the difference in the time of flight ͑TOF͒ of detected photons.
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Unlike SPECT, in TOF-PET the reconstruction algorithm does not assume that an annihilation occurred somewhere on the Line of Response ͑LOR͒, but follows a probability distribution around a point that is determined by TOF information, which can significantly improve resolution. 113 Besides technological improvements, advances in PET radiochemistry may further assist its spread in biological research. New tracers based on gallium-66 and 68, ͑available by 68 Ge/68 Ga generators͒, copper ͑produced by a medium cyclotron͒, and other interesting PET radioisotopes such as Tc-94m, I-124, Y-86, and Rb-81 and 82, are being designed and assessed by several research groups. 114, 115 They offer the advantages of relatively easy production, as well as the potential to transfer SPECT radiochemistry in PET, thus taking advantage of a number of already evaluated SPECT tracers.
PET moved quickly from brain imaging to oncology. The glucose analog F-18-fluordeoxyglucose ͑FDG͒ is a robust biochemical marker of cellular transformation and PET is a standard clinical tool for cancer diagnosis, characterization, treatments planning, staging, as well as early response therapy. 116 Advances in PET radiopharmaceuticals and PET radiochemistry have opened the road to more specific PET applications besides oncology, such as myocardial viability, 117 brain diseases, 118 and immunology. 119 Preclinical biological research has benefit from the introduction of high sensitivity small PET scanners with submillimeter resolution and numerous applications ranging from oncology, gene expression, and multidrug resistance. Angiogenesis is another attractive area, where PET has been used for in vivo imaging of avb3 integrins, VEGF, and activated endothelial cells. 104 Absorbed radiation dose in preclinical PET studies is being studied over the past five years, using Monte Carlo simulations and anatomically defined mice phantoms. 120 It is impressing that calculated doses, although lower than the lethal, are more than ten times higher than for human PET studies. For example, in a typical injection of 200 Ci of FDG, absorbed dose ranges from 19 mGy for skin to 4000 mGy for bladder wall. Depending on the application, a large variation in radiation dose is observed since some tissues can accumulate tracer, while others are involved in the clearance of the tracer from circulation and receive higher radiation doses. For this reason, accurate absorbed dose calculations are necessary, especially when repeated imaging tasks are planned. The latter is something that seems to be neglected by most groups.
VIII. OPTICAL IMAGING
Optical imaging methods depict the distribution of a tracer in a target area, similarly to nuclear medicine, without using ionizing radiation. Those tracers emit optical photons, which are detected by a CCD system. Optical imaging can be divided into fluorescence imaging ͑FLI͒ and bioluminescence imaging ͑BLI͒. Bioluminescence is a normal process in animals such as the firefly that express an enzyme called luciferace as a result of photochemical reactions. In BLI, cells of interest have to be engineered first in order to express luciferace and then induced in the small animal. A typical application is tumor imaging. Intraperitoneal injection of luciferin results into its oxidization by luciferace and light is produced 10-12 min after luciferin injection. This light signal is detected by a CCD camera and planar intensity images are produced. Since there is no autofluorescence background, BLI is a highly sensitive technique and only a few cells even relatively deep inside the tissue can be tracked. 121 On the other hand, in FLI, the optical signal comes from a fluorescent molecule that can be either endogenous ͑collagen or hemoglobin͒ or injected ͑green fluorescent protein and other optical contrast agents͒. An external light source is used to excite the fluorophore and a CCD detects the lower energy emission light. Additional imaging components are filters that select excitation and emission wavelengths. 122 The main drawback of optical imaging is the strong absorption and scattering of optical photons that can travel only a few millimeters, which limit its application to small animals. 123 However, near-infrared fluorescence ͑NIRF͒ with emission wavelengths between 650 and 900 nm allows imaging at greater depths. Current research is focused in the development of new NIRF probes and dyes, which will not raise toxicity issues. 124 A second challenge in optical imaging is the acquisition of tomographic images, known as fluorescence tomography. Photons' scattering and attenuation FIG. 9 . Successive coronal slices of a normal mouse injected with FDG, using a custom-made preclinical PET system, based on two H8500 PSPMTs and LSO crystals ͑estimated spatial resolution in the center of the field of view is 2 mm͒. Note the higher concentration in the heart and brain and the lower concentration of the tracer in the bones.
varies according to their wavelength and the organs and tissues through which they penetrate. In fluorescence, tomography light coupling is performed using fibers in contact with the imaged object or contact-free detection. The first mode limits flexibility. In the second mode, model-based reconstruction methods have to be used, whose optimization is an open issue. 125 Although the short penetration depth limits optical imaging applications mainly to preclinical imaging, some applications such as breast imaging has provided encouraging results. 126 On a preclinical level, the high sensitivity and throughput has made optical imaging even more popular than PET in oncology, gene expression, and in vivo stem cell tracking. 127, 128 Novel applications in angiogenesis include imaging of VEGF, avb3 integrin, and matrix metalloproteinase activity.
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IX. MULTIMODALITY HYBRID IMAGING AND THERAPY
There is no perfect imaging modality. All have limitations either on the technical level ͑e.g., resolution or sensitivity͒ or on the application level ͑e.g., availability of appropriate tracers͒. Each imaging modality has its own advantages and limitations and acquired information is actually complementary between them. The rationale of multimodality imaging is to combine a low-sensitivity modality with high spatial resolution and tissue contrast ͑CT or MRI͒ with another lowresolution but high-sensitivity modality. 7, 9 Development of multimodality imaging platforms is exceedingly challenging because it requires simultaneous or consecutive data acquisition with appropriate image registration and compatibility of different data formats to achieve final fusion of the studies in a single multiplanar reformatted cross-sectional examination. Commercially available systems for clinical practice and appropriately modified for preclinical small-animal research include PET-CT, SPECT-CT, PET-MRI, or even PET-CT-MRI ͑Fig. 10͒. 130 For example, multimodal targeted SPECT-CT/MR imaging of VX2 tumors implanted in rabbits has been used for high-sensitivity detection of tumor angiogenesis coupled with high-resolution monitoring of responsiveness to antiangiogenic therapy. 131 It should be noted that motivation for new hybrid detectors has become application driven; in the early days of multimodal imaging, developers aimed to integrate available technologies, provide new tools, and then seek potential applications. Nowadays end users define the requirements of a hybrid system based on the questions: ͑a͒ What do we want to see? ͑b͒ Which modalities are available? ͑c͒ Does merging two or more modalities provide additional temporospatial information? Multimodal information can be valuable in a number of applications; angiogenesis is such a typical example. Software image fusion partially addressed those needs, mainly in motion-free regions such as the skull. Although a valuable tool, random or normal motion can strongly affect image quality, especially where submillimeter spatial resolution is needed. 132 Hybrid systems that merge two or more modalities can benefit from their advantages and overcome their limitations. The obvious combination of merging detailed x-ray anatomical imaging with functional information of PET or SPECT was proposed in the late 1990s. Simple sequential systems that allowed hardware fusion of scintigraphic and x-ray images provided accurate localization of tracer's concentration in planar and tomographic mode. 133 Based on the same sequential architecture, clinical PET/CT made a breakthrough in nuclear medicine market and almost eliminated standard PET scanners. 134 SPECT/CT followed PET/CT and is gaining acceptance in the medical community. 135 As a consequence, major vendors were convinced to construct small hybrid ͑CT/SPECT/PET͒ scanners for preclinical studies and depending on the user needs and budget, some or all those options are available. Smaller companies or research laboratories offer low cost efficient hybrid imagers. There are two main advantages of merging anatomical with functional information. The first is the accurate localization of hot spots, which may be useful for nonexperienced end-users, e.g., biologists, or even critical for diagnostic purposes, e.g., bone metastasis. 136 The second has to do with the use of anatomical information for attenuation correction, 137 although there are still open issues. However, the real challenge is the true integration of different modalities in a single detector and the simultaneous acquisition of multimodal data.
Among all combinations the most mature technology at the moment is the integration of PET and MRI, which offers the combination of high resolution, soft tissue, anatomical information of MRI, and high sensitivity of PET. 138 PET-MRI may provide excellent molecular imaging coupled with detailed anatomical reference of the detected process. Initially, simultaneous PET-MRI was realized by placing the crystals of the PET system inside the MRI and by using optical fibers to drive light to the PMT. 139 The introduction of APDs ͑Ref. 140͒ and, more recently, SiPMs ͑Ref. 141͒ offers alternative detector modules to the PMTs, which do not interfere with the magnetic field, making the first preclinical and clinical prototypes available. 130, 142 The true integration of SPECT/MRI will add MRI benefits to the wellestablished SPECT imaging. However, rotating components and collimator possess additional design constraints. Currently, research groups are working toward the integration of PET/SPECT with CT, aiming to overcome the limitations of current sequential approaches. 143 The first optical imaging and PET prototype has been designed and initial results demonstrate its potential in preclinical research. 144, 145 There are some less obvious combinations for multimodal systems technology including optical with CT, 146 x ray with MRI, 147 and optical with MRI.
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X. IMAGING PROBES
Imaging probes can be single molecules or even large complexes that are designed to target specific receptors or disease specific molecular processes. 149 They carry one or more agents that provide a signal which can be detected by a suitable imaging modality. A variety of such agents can enhance this signal and thus image contrast by taking advantage of physical mechanisms ͑usually radiation matter interaction͒ on which the modality is based. 150 Imaging probes can be only diagnostic or therapeutic as well. Diagnostic probes bind to the target without initiating pharmacologic effects. Therapeutic probes inhibit or block targets that are involved in key molecular processes thus reaching curative effects, while also providing an imaging signal. 151 An imaging probe has to be target-specific for the application of interest. This is achieved by binding the signaling agent to a carrier molecule. The optimal carrier has biological properties that allow accumulation at the target with high specificity, sufficient temporal localization to allow imaging, no or negligible side effects, and relatively simple and low cost chemistry. 152 Along with downscaling of imaging modalities, design and development of new reporter probes and imaging contrast agents is paving the way toward tissue-specific targeting of cellular ligands. 3 Targeted drug delivery is inherently associated with reduced systemic drug levels and may result in reduced drug toxicity and unwanted side-effects. 153 Engineering of targeted contrast agents with high site-specific signal-to-noise ratio is a prerogative for hybrid models of diagnosis and therapy and the emergence of personalized custom-made therapies in the future. To that end, dualfunction imaging techniques are gaining widespread interest. Contrast agents used for targeted imaging of surface cell molecules may be further modified and employed for direct selective drug delivery. 154 Appropriately designed nanoparticles could combine contrast agents and drug therapy, permitting simultaneous detection and destruction of tumor cells or combination of imaging and treatment of cardiovascular disorders.
Nanotechnology actually refers to the measurement and manipulation of material at the nanoscale. Current nanotechnology engineering techniques permit the synthesis of nanoparticles with multivalent, multifunctional probes, highly efficient targeting, enhanced biocompatibility, and high drug loads capacity. 155 Nanoparticles measuring a few nanometers across may be coated with various ligands or probes achieving multivalent binding and resulting in dramatically increased uptake and retention of the particles and their content and increased molecular imaging signal-to-noise ratio.
11 Particularly elegant advantages of nanoparticles include their lengthy circulation times, the potential to carry high drug loads, the ease of integrating multiple target ligands, and excellent contrast production, i.e., sophisticated quantum dots. 156 Biological camouflage of the nanoparticles with appropriate coatings may help them evade immunological attack and early destruction.
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XI. ULTRASOUND MICROBUBBLES
Typically, ultrasound images are generated by the acoustic echoes produced by high-frequency acoustic waves traveling through tissues.
1 Ultrasonography generates tissue contrast on the basis of variant compressibility of different tissue layers. Gases have significantly higher compressibility than soft tissues. This inherent gas property is exploited by contrast agents specifically designed for ultrasound. Microbubbles in the size of 1 -5 m are engineered by encapsulation of a gas within a biodegradable shell. 17 The gas used can be air that dissolves quickly in water or sulphurhexafloride ͑SF 6 ͒ or perfluorocarbons ͑C 3 F 8 ͒ that are less soluble and provide sustained contrast effect. The shell of the microbubbles determines the acoustic impedance difference of the contrast agent and may be produced by phospholipid micelles, albumin, cyanoacrylate, or other polymer constructs. 17 Microbubbles produce strong tissue contrast when entering the ultrasound field that depends on the acoustic energy of the emitted ultrasound beam, also called the mechanical index or pressure amplitude. At low energies, microbubbles simply reflect and scatter the beam; at medium energies, microbubbles will start to oscillate as the ultrasound frequency approaches their resonance frequency; and at high acoustic energies, microbubbles will burst producing a high contrast signal, also called "stimulated acoustic emission." 17 The released gas bubbles are then exhaled from the lungs and the outer shell components are broken down by body metabolism. In contrast with microbubble-enhanced ultrasound imaging with a low mechanical index where sustained tissue contrast is achieved without destruction of the microbubbles, the use of a high mechanical index can identify a single bursting microbubble in the tissue but requires continuous contrast replenishment for real-time imaging. 157 Of note, however, contrast-tissue interaction during insonation of mi-crobubble constructs may include formation of cavitation nuclei, capillary leakage, and cell destruction. 158 These properties can be exploited in the interest of local therapy such as the acceleration of pharmaceutical thrombolysis and enhanced gene and drug therapy by sonoporation, i.e., opening of cell membranes by application of acoustic energy. 159 Gadolinium or SPIO loaded microbubbles have been engineered to serve as dual contrast agents for combined ultrasound and MRI imaging. 160, 161 Microbubbles can be loaded with active drug substances and linked to probes that are designed to bind with high affinity to cell-specific surface antigens. Selective microbubble targeting can be achieved by linking them with antibodies, carbohydrates, nucleotides, peptides, or other multivalent probes ͑Fig. 11͒. Soon after distribution and binding of the targeted microbubbles, ultrasound is employed for their destruction to achieve sitespecific delivery of their bioactive payloads. 162, 163 Contrary to air-filled microbubbles that typically stay in the intravascular space, perfluorocarbon nanoparticles may also aim extravascular targets. 164 Appropriately designed microbubbles have been proposed for ultrasound-guided cancer therapy with tailored drug and gene delivery. 165 Microbubbles carrying ligands that target cellular adhesion molecules including but not limited to ICAM-1, VCAM-1, L-selectin, and P-selectin have been applied for selective imaging of inflammation in the context of ischemia or cancer. [166] [167] [168] Use of avb3-targeted perfluorocarbon nanoparticles for highsensitivity detection of tumoral neovascularization has received worldwide interest and represents a novel noninvasive approach for assessment and targeting abnormal networks of angiogenesis.
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XII. CT CONTRAST AGENTS
Even though noncontrast-enhanced CT ͑NECT͒ has a high spatial and temporal resolution and high for elements with a high atomic number like bones, NECT imaging of soft tissues inherently suffers from low contrast resolution, e.g., low contrast-to-noise ratio ͑CNR͒. Therefore, administration of contrast media is essential for high-quality soft-tissue imaging of small animals. 9 Water-soluble iodinated contrast media are routinely used in in vivo CT applications to increase x-ray attenuation of blood and thereby enhance softtissue contrast on the basis of its differential tissue perfusion. Alternative contrast media developed for CT imaging comprise iodinated polymer agents, 173, 174 water-soluble gadolinium chelates, and liposomal nanoparticles loaded with x-ray attenuating agents. 175, 176 Blood pool contrast media represent a new generation of conventional iodinated contrast media specifically engineered to avoid renal excretion and preferentially stay in the intravascular space for a long time, thereby providing a strong, long-lasting enhancement of blood vessels and highly vascularized intra-abdominal solid organs. Rodents typically possess very short circulation times with heart rates at least five times faster than humans and first-pass contrast studies are not feasible. 9, 177 Thus, with the exception of skeletal imaging, blood-pool contrast agents are necessary for the majority of micro-CT applications to increase the window interval of adequate vessel and soft-tissue enhancement and allow high-resolution protocols with increased scan time. Novel compounds mainly include lipid-emulsion formulations of conventional iodinated contrast media ͑under the commercial names Fenestra VC and Fenestra LC͒. [178] [179] [180] The Fenestra product line is based on iodinated triglycerides contained in the lipophilic cores of oil-in-water lipid emulsions similar to the naturally occurring chylomicron remnants. Use of such lipid-conjugated contrasts with iodine concentration greater than 100 mg I/ml is particularly useful in micro-CT imaging of small animals with extremely short contrast circulation lifetime. 178 Avoidance of renal clearance and phagocytosis by the reticuloendothelial system with sustained delayed enhancement of the aorta down to submillimeter vessels with cardiac blood-pool attenuation more than 500 HU even up to 2 h postinfusion has been observed in murine models. 178 Apart from detailed imaging of cardiac and peripheral murine angioarchitecture, iodinated liposome-based contrasts have been used for accurate delineation of liver micrometastasis around 250 m in mice. 181 Theoretically, design of newer targeted nanoprobes incorporating heavy metals will significantly increase SNR and CNR of micro-CT in the future. For example, bismuth-sulfide coated nanoparticles have been used for prolonged vessel, liver, and lymph node imaging in mice exhibiting fivefold higher x-ray attenuation than conventional iodine. 182 Interestingly, multimodal liposomeencapsulated contrast constructs containing both iodine and gadolinium have been developed for combined computed tomography and magnetic resonance imaging applications even up to 3 days after contrast administration. 9, 183 In terms of physical modifications, K-edge subtraction and x-ray fluo- rescence imaging have been proposed for improved soft tissue contrast. 30 A higher x-ray dose, i.e., increased photons fluence, may be used to further increase spatial resolution at the expense, however, of a geometrical increase of delivered dose.
XIII. MRI CONTRAST AGENTS
MRI contrast agents are typically composed of paramagnetic metal chelates, i.e., gadolinium/ Gd +3 , or superparamagnetic iron oxide, i.e., SPIO or USPIO, that enhance proton relaxivity of water molecules and significantly increase tissue contrast. 7 These contrast compounds may be extracellular or intracellular or reside in the blood pool depending on their biodistribution, renal clearance and cellular uptake. [184] [185] [186] With a view to diagnose renal injury early before elevation of serum creatinine, macromolecular polyamine dendrimer-based contrast agents have been synthesized and successfully applied in mice MRI imaging. 187 Polymeric contrast agents have been also developed for MRI applications. Polymeric nanocapsules incorporating various commercial gadolinium chelates have been synthesized to act as contrast microvehicles. 173, 174, 188 Such nanoparticles can be further engineered to target specific deep tissue structures, thereby increasing contrast against background tissue and achieving high-sensitivity MRI imaging of cancer and atherosclerosis disease models. Noninvasive deep tissue imaging with targeted MRI contrasts can be also exploited for ex vivo or in vivo cell labeling and tracking, gaining invaluable insights into cellular interactions and responses regulating various complex biological processes. 189, 190 Liposomal formulations of conventional MRI contrast agents that evade renal clearance and portray prolonged residence in the blood pool are becoming increasingly useful in small animals with extremely rapid circulation and contrast clearance. 191, 192 Novel powerful MRI contrast agents have also been developed with noncovalent linking of carbon nanostructures such as C60 fullerenes and nanotubes with gadolinium, otherwise called gadonanotubes. 193, 194 Targeted paramagnetic substrates with amplifiable signal properties for high-sensitivity small-animal molecular imaging has been recently described. 195 Focusing on the assessment of angiogenesis as a treatment end point of various cancer treatments, dynamic contrastenhanced MRI after intravenous administration of gadolinium chelates is the current standard-of-care that has also been widely adopted in murine cancer research. 7, 196 Longitudinal in vivo monitoring of tumor growth in transgenic animals and response to ablative therapies is one of typical micro-MRI applications.
1 MRI has been applied for early characterization of cancerous tissue in relevant animal models of brain, 197 prostate, 198 and breast cancer. 199 Preclinical MRI has been extensively applied for understanding local tumor invasion, providing insights into the fundamentals of angiogenesis and elucidation of metastatic dissemination of cancer. Dynamic contrast-enhanced MRI allows indirect morphological assessment of angiogenesis after quantitative analysis of tissue enhancement dynamics. Gadoliniumenhanced MRI studies elegantly portray tumoral neovascularization characterized by increased capillary surface permeability, microvessel vasodilation, and abnormal vessel sprouting with a high sensitivity. [200] [201] [202] Surrogate end points such as blood volume, blood flow, transit time, and capillary permeability can be quantified by dynamic contrastenhanced MR perfusion and diffusion imaging for accurate diagnosis of early ischemia or abnormal tumor enhancement. 199 Calculation of sophisticated parameters such as ADC with dedicated magnetic resonance diffusion sequences is of utmost sensitivity for detection of early cell membrane disruption by ischemia. 203 Blood oxygen level dependent ͑BOLD͒ algorithms are available for noninvasive magnetic imaging of blood oxygenation in normal and cancerous tissues. 204 BOLD MRI has been applied for blood flow and oxygenation measurements for baseline evaluation of xenograft as well as monitor the response to treatment. 205 To another end, a variety of macromolecular MR contrast media exploiting the hyperpermeable state of abnormal tumor vessels have been developed over the past decade. Interestingly, enhancement patterns of these new MR contrast agents have been reported to correlate with ex vivo microvascular density, tumor grade, and response to antiangiogenic therapy. Targeted angiogenesis imaging and delivery of payloads of antitumoral agents has been also proposed for this new class of MR contrast agents.
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XIV. RADIONUCLIDE TRACERS
Diagnostic SPECT radionuclides are usually metals with a half-life ranging from a few hours ͑e.g., 6 h for Tc99m͒, up to some days ͑e.g., 3 days for Tl201͒. The energy of the emitted gamma photons also ranges from 140 keV for Tc99m to 245 keV for In111. 207 Tc99m can be produced by Mo99/ Tc99m generators, which makes it easily accessible for many hospitals and radiobiological laboratories. As a result it is by far the most utilized isotope in nuclear medicine. Hundreds of Tc99m based radiopharmaceuticals have been developed and evaluated. Many of them are already introduced in clinical practice or have provided encouraging preclinical results. Tc99m radiochemistry has been in the center of interest for all cancer related processes including angiogenesis. Although the carrier molecule determines which angiogenesis targets will be imaged, Tc99m based derivatives have been evaluated for most of them, mainly due to its availability, well studied radiochemistry, and optimal imaging properties. Typical examples include imaging integrin avb3 with Tc99m radiolabeled RGD peptides, 208 VEGF and its receptors with Tc99m labeled antibodies, 209 activated endothelial cells with Tc99m-endostatin, and MMP with 99mTc-labeled CTT. 210 Finally, several Tc99m based tracers have been already developed for imaging tumor receptors of cancer cells and this information is valuable when studying specific angiogenesis mechanisms.
Other SPECT radioisotopes have been attached to carriers that target angiogenesis, offering a variety of derivatives with different imaging properties and obviously radiochemical preparation. RGD peptides targeting integrin avb3 have been radiolabeled with I125, 211 which, however, has a half-life of 60 days that is too long for routine preclinical and clinical studies. On the other hand, In111 labeled RGD peptides with a half-life of ϳ2.8 days are suitable for longer imaging studies, while In111 photons ͑171 and 245 keV͒ can be easily separated from Tc99m photons ͑140 keV͒, offering the potential of simultaneous imaging. 212 VEGF has been targeted with I125, 213 In111, 214 and I123 with a half-life of 13.22 h. 215 Activated endothelial cells have been targeted with I125-angiostatin 216 and several MMPs with a number of compounds labeled with I111, 217 I125, 218 and I123. 219 Standard PET radionuclides are F18, C11, N13 and O15, which are smaller molecules compared to SPECT metals, which are characterized by short half-life ͑ϳ2 h, ϳ20 min, ϳ10 min, and ϳ2 min, respectively͒. In addition C, N, and O are structural compounds of all organisms, something that adds more flexibility to radiobiologists. Long-lived and generator-based radionuclides are under active research interest due to their easier manipulation and their similarities with SPECT radiochemistry. 220 While FDG-PET has become a standard diagnostic technique for whole body cancer detection, a number of new F18 based agents have reached clinical bed with FLT providing the most promising results as a proliferation marker. 221 More PET radiopharmaceuticals that allow specific measurement of tumor growth and metabolism have and are still being developed and evaluated. 220 PET radioisotopes have the disadvantage of resulting to 511 keV photons despite their kinetic energy. However, the high sensitivity of the method when compared to SPECT and the development of high resolution small scanners increased PET role in angiogenesis research. The labeling of RGD peptides for avb3 targeting has been successfully achieved with F18 and has been compared to standard FDG ͑Ref. 222͒ and Cu64. 223 VEGF and related receptors have been radiolabeled and successfully imaged not only with fluorine derivatives 224 but also with other PET isotopes. 225 PET imaging of activated endothelial cells is reported using 4-͓18F͔Fluorothalidomide, 226 as well as 2-͓11C͔Methoxyestradiol. 227 More than 20 enzymes are found in MMPs and numerous publications demonstrate radiolabeling and imaging of their inhibitors mainly with F18 ͑Ref. 228͒ or C11. 229 What are important to highlight are the perspectives of combining more than one radiotracer. Having the same carrier labeled with different isotopes allows monitoring the temporal evolution of angiogenesis. For example, spatiotemporal information on the number of activated endothelial cells could be obtained by injecting a RGD peptide labeled with Tc99m on day A and the same peptide labeled with In111 on day B. Tc99m can be detected up to 1-2 days postinjection, while In111 is visible for more than a week. If Tc99m is not present in day B then the comparison of the two imaging studies can provide qualitative or even quantitative information for the potential increase ͑or decrease͒ in the number of activated endothelial cells. If both isotopes are present, then it is possible to have some receptors blocked with Tc99m-RGD peptide and the newer receptors targeted by the second In111 injection. Exciting applications would arise when simultaneously injecting different carriers that, e.g., target integrin avb3 and VEGF receptors, labeled with different SPECT radioisotopes, so that complementary or antagonistic mechanisms can be studied in vivo. Another feasible perspective is the combination of FDG-PET that monitors glucose metabolism in tumor cells, along with SPECT labeled carriers that target specific angiogenesis processes. Really challenging, although more complicated, would be the use of short lived PET isotopes in combination with SPECT tracers taking advantage of their different timing, energy and biological characteristics.
XV. FLUOROPHORES
Bioluminescence imaging detects light produced by the enzymatic reaction of a luciferase enzyme with its substrate, with firefly luciferase ͑Fluc͒ being the most frequently used in molecular imaging, with a peak at 560 nm. 230 Since light absorption and scattering decreases when emission wavelength becomes higher, other luciferaces have been used as optical probes; pyrophorusplagiophthalamus oxidizes luciferin and produces green-orange ͑544 nm͒ or red ͑611 nm͒, something that has potential advantages in in vivo applications, although less light compared to luciferase is generated. Renilla luciferase ͑Rluc͒ and Gaussia luciferase are smaller than Fluc and ATP-independent; they react with a different substrate, coelenterazine, but they produce light with peak emission ϳ480 nm. 231 Current efforts aim to shift the peak wavelength of Rluc toward the red ͑termed as hRluc͒, in order to increase small-animal imaging applications. 232 The availability of more than one luciferase enzyme has similarities to the use of two different SPECT isotopes and could allow multiple biologic processes to be imaged if monitored in vivo, using appropriate spectral filters and substrates. 233 Bioluminescence is a valuable technique in preclinical research, including tumor imaging and angiogenesis, although it seems that it will find only limited human applications due to its limited depth penetration. Bioluminescence is used to target tumor cells and it may provide highly valuable differential information when combined with a second ͑optical or not͒ technique that images specific angiogenesis targets. 234 Recently, RGDPEG-AdLuc, a RGD peptide that encodes firefly luciferase reporter gene ͑AdLuc͒, provided in vivo bioluminescence images of integrins receptors. 235 On the other hand, fluorescence imaging uses target fluorescent molecules that are excited by an external source and emit longer-wavelength light and several probes are created. Fluorescent protein-based indicators can be designed to respond to a variety of biological events and signals, targeted to subcellular compartments, introduced into a wide variety of tissues and intact organisms, and very rarely cause photodynamic toxicity. 236 Engineering of the green fluorescent protein has led to new variants with enhanced brightness, improved pH resistance and emission at cyan and yellow wavelengths.
237,238 NIR fluorophores offer improved tissue penetration and emission over 800 nm with recent research focusing on the class of cyanines dyes NIR fluorescent probes. 239 Compared to bioluminescence, fluorescence offers more flexibility in angiogenesis in vivo imaging. For avb3 integrins, cyanine dyes such as Cy5.5 coupled to RGD-peptides allowed NIRF imaging of tumor xenografts in mice, as well as fluorescence-mediated tomography. [240] [241] [242] Cy5.5-VEGF has been used for in vivo NIRF imaging and recently VEGF/ Cy7 successfully targeted deeply seated tumors. 243 NIRF has been used for MMPs targeting in the pathophysiology of cerebral ischemia 244 and tumor angiogenesis. 245 Since it is possible to use more than one fluorophores and different excitation wavelengths, simultaneous imaging targeting of different angiogenesis processes is technically feasible. Furthermore, the combination of bioluminescence with fluorescence further expands their preclinical value, although it raises animal manipulation complexity.
XVI. COMBINED IMAGING AND THERAPY
An alternative and relatively recent approach to cancer treatment is through angiogenesis, e.g., blocking blood flow to a large number of cancer cells by targeting a single point of a vessel. Despite the fact that preclinical results have not been successfully transferred to clinical practice, it remains a field of active research promising to understand and exploit the complicated processes that correlate angiogenesis and tumor growth. 246, 247 Antiangiogenic drugs such as bevacizumab ͑Avastin͒, sunitinib ͑Sutent͒, and sorafenib ͑Nexavar͒ are available. 248 It is here where in vivo imaging may illuminate the key mechanisms and bridge the gap between success in animal and failure in human trials and several recent publications support this hypothesis. Although numerous studies are using molecular imaging as a technique to qualitatively assess and quantify the efficacy of angiogenic treatment, [249] [250] [251] [252] we will focus on some examples, where imaging is combined with therapy.
Scintigraphic imaging of In111-labeled bevacizumab suggested that its accumulation in the tumor is due to interaction with VEGF-A isoforms, which are associated with the tumor cell surface and/or the extracellular matrix. 253 PET scanning with Zr89-bevacizumab has been proposed as a new tracer for noninvasive in vivo imaging of VEGF in the tumor microenvironment. 254 A relatively simple approach is labeling of anti-VEGF monoclonal antibodies with therapeutic radioisotopes, e.g., Lu177, which emit gamma rays, allowing imaging with scintigraphic methods. 255 Furthermore, paramagnetic and fluorescent liposomes, containing angiostatic therapeutics, have the advantage of allowing imagesupervised drug delivery and subsequent monitoring of therapeutic efficacy. 256 Finally, multifunctional nanostructured materials containing anticancer drugs, targeting probes, and imaging agents will provide the means for in vivo monitoring of simultaneous angiogenic therapy. [257] [258] [259] The potential to combine ͑a͒ a magnetic core ͑which can induce hyperthermia and be imaged with MRI͒, ͑b͒ fluorescent probes or radioisotopes ͑that can be imaged͒, ͑c͒ therapeutic radioisotopes, and ͑d͒ anticancer and angiogenic drugs opens numerous research paths that will be investigated in the upcoming years.
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XVII. GLIMPSE INTO THE FUTURE
Diagnostics are gradually being merged with therapeutics toward a novel pathway under the name of theragnostics, which represents an innovative paradigm shift of biological sciences. Multimodality platforms of bioinformatics with automatic coregistration and integration of imaging and biological data, including but not limited to cross-sectional anatomical and functional images, optical imaging, gene and protein expression, studies of pharmacokinetics and pharmacogenomics, histology, and cell microscopy, will have to be developed to handle complex biomedical information originating from multiplexed imaging and other sources in order to decipher the scribbles of life.
Preclinical imaging is rapidly moving from oncology and radiopharmaceutical research to new domains and it is continuously gaining field as a valuable tool for molecular medicine applications. The benefits of noninvasive, in vivo information ͑qualitative and quantitative͒ change the way that researchers think and practice. The possibility to carry out long time studies in the same animal has tremendous advantages compared to standard ex vivo studies. However, multimodal imaging technology is still in its infancy and there are improvements that need to be realized in order to solve current practical limitations, as well as address emerging challenges.
Spatial resolution seems to reach the physical limits in most techniques and it is adequate in applications that investigate the existence or not of a specific marker, the activation or not of a specific process, and the targeting or not of a specific receptor. Although further improvement in resolution is welcome, the spatiotemporal information provided by in vivo molecular imaging can be completed by additional ex vivo studies in the optimal time points. In vivo imaging can therefore be considered as a high throughput technique that will identify possible markers or phenomena for more detailed ex vivo studies. Since time-dependent phenomena are of major interest, the main imaging parameter that needs to be improved is sensitivity, especially in tomographic imaging. In case of SPECT, very few full ringlike scanners exist that are capable of performing 4D imaging. Systems based on rotating heads fail to acquire fast projection data, at least with current reconstruction algorithms. Further research on multipinhole cameras with helical rotation or full ring geometries with appropriate collimators, pixilated crystals, and photodiode arrays can, in principle, lead to systems with increased sensitivity at the price of high cost. The latter is a key parameter, since the wide application of multimodal imaging systems and the increase of their end-users will push molecular research. On the other hand their spread is related to their overall cost, which needs to be kept relatively low, if a large user community is envisaged. To this direction, static systems that allow dynamic studies have the potential to provide approximate tomographic information, by using limited angle reconstruction algorithms. Although their accuracy has to be proven, this potential seems quite feasible for PET. Combination of different modalities in elegant multimodality platforms like PET-CT or PET-MR that can acquire fused morphological and functional information of anatomy and pathology paves the way toward a unification of imaging technologies with tremendous benefits for preclinical sciences.
A final but important consideration in small animal imaging has to do with animal manipulation, since unlike ex vivo studies, small animals are anaesthetized during imaging studies. Animal vital signals need to be continuously monitored. Still, longitudinal studies pose additional complexities and the effect of anaesthetization needs to be carefully evaluated to avoid misinterpretations. Medical physicists have a strong and unique role in key areas of imaging technology, bioinformatics, and experimental ethics to optimize and improve throughput dynamics of small-animal preclinical and translational research that will in turn be the driving force for gradual convergence of diagnostics with therapeutics toward theragnostics coupled with the development of targeted individualized therapies for the human of the future. Design and development of responsive, so called "activatable" or "smart" nanoparticles that will serve as ultrasensitive contrast agents, probes, tracers, or even nanoinstruments for diagnosis, therapy and cell manipulation on the cellular and molecular level is the "holy grail" of biology and medicine in the 21st century. For example, nanoprobes with basic intelligence could detect subtle differences in extracellular or intracellular environment, like pH, pO 2 , specific activity or levels of specific metabolites, and react accordingly upon reaching a predetermined threshold. Pioneering concepts of nanoengineering include modular multifunctional nanostructures, cooperative nanostructures acting synergistically, sitespecific activatable nanostructures, and nanostructures with nonspherical multidimensional designs creating new avenues of tissue-probe and tissue-drug interaction and therapy. 155 In conclusion, accelerating advancements in biotechnology and nanotechnology coupled with our recently increased depth of knowledge of the human genome and subcellular anatomy have ignited a revolution in modern medicine. New proofs of principle are already driving a groundbreaking transformation of everyday clinical practice toward targeted diagnostic approaches and tailoring of individualized custom-made therapies.
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